Molecule News and Research

RSS

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

Diamyd Medical AB reports that the Company has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd and to initiate closure of the study.

23 Jun 2011

Molecularly targeted glue for cancer

"This is a totally new approach to cancer therapy," says Professor Patrick Gunning of the Department of Chemical and Physical Sciences. "Everything prior to this has targeted functionally relevant binding sites. Our approach inhibits the mobility of cancer-promoting proteins within cells-essentially, it's like molecularly targeted glue."

23 Jun 2011

VENENUM opens new medicinal chemistry facility in Hamilton, NJ

VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify potential therapeutic agents against its novel disease-based targets, or its partners' targets, announced today that it opened its new medicinal chemistry space at 8 Black Forest Road in Hamilton, NJ.

22 Jun 2011

Two NJIT researchers receive U.S. Patent for nanoprobe array technique

Reginald C. Farrow and Zafer Iqbal, research professors at NJIT, were awarded a patent today for an improved method of fabricating arrays of nanoscale electrical probes. Their discovery may lead to improved diagnostic tools for measuring the spatial variation of electrical activity inside biological cells.

22 Jun 2011

Scientists discover molecular mechanism that could help develop new MS treatments

Scientists at The University of Nottingham have discovered a molecular mechanism which could bring about the development of new treatments for Multiple Sclerosis (MS) — a chronic inflammatory disease of the central nervous system.

22 Jun 2011

Novel method of disguising nanoparticles as red blood cells to fight cancer

Researchers at the University of California, San Diego have developed a novel method of disguising nanoparticles as red blood cells, which will enable them to evade the body's immune system and deliver cancer-fighting drugs straight to a tumor. Their research was published this week in the online Early Edition of the Proceedings of the National Academy of Sciences.

22 Jun 2011

Palatin receives U.S. patent titled ‘Amino Acid Surrogates for Peptidic Constructs'

Palatin Technologies, Inc. announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,964,181, titled "Amino Acid Surrogates for Peptidic Constructs."

22 Jun 2011

TESARO secures $101M in Series B financing

TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $101 million in a Series B financing to advance and expand the Company's cancer product portfolio.

21 Jun 2011

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.

20 Jun 2011

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that positive data are being presented by its collaborator Genentech, a member of the Roche Group, from a pivotal Phase II clinical trial conducted by Roche and Genentech of vismodegib in patients with advanced basal cell carcinoma, an often life-threatening form of skin cancer that can have disfiguring and debilitating effects.

20 Jun 2011

Positive data from Ischemix CMX-2043 Phase 2a trial for peri-operative cardiac ischemia-reperfusion injury

Ischemix today announced positive top line data from a Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative cardiac ischemia-reperfusion injury.

17 Jun 2011

Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary research and development to advance Sunshine's lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials.

17 Jun 2011

Precisely mapped allosteric binding site will facilitate design of drugs with minimal side effects

Structural biologists at Cold Spring Harbor Laboratory (CSHL) have obtained a precise molecular map of the binding site for an allosteric inhibitor in a subtype of the NMDA (N-methyl-D-aspartate) receptor, which is commonly expressed in brain cells.

17 Jun 2011

Scientists reveal complex protein mechanism that regulates genes linked with cancer

Scientists at Memorial Sloan-Kettering Cancer Center in New York and at IRB Barcelona reveal the mechanism of action of a protein that is essential for life and is associated with disease.

17 Jun 2011

Scientists uncover how immune system responds to invading anthrax bacteria

Scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have uncovered how the body's immune system launches its survival response to the notorious and deadly bacterium anthrax.

17 Jun 2011

Positive results from etanercept pilot study against dermatomyositis

A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy.

17 Jun 2011

UCLA researchers find new potential therapeutic target for preventing HIV

Specific types of "helper" T cells that are crucial to maintaining functioning immune systems contain an enzyme called PDI. This enzyme affects how proteins fold into specific shapes, which in turn influences how the T cells behave.

16 Jun 2011

VARI researchers discover protein linked to spread of head and neck cancer nasopharyngeal carcinoma

In a study recently published in Cancer Research, Van Andel Research Institute (VARI) researchers found a protein that could help predict the spread of the head and neck cancer nasopharyngeal carcinoma (NPC); this protein could also serve as part of a treatment strategy to stop the spread of the disease.

15 Jun 2011

Scientists discover Sonic Hedgehog protein's mechanism of action

A scientific breakthrough by researchers at the Institut de recherches cliniques de Montréal (IRCM) will be published tomorrow in Developmental Cell, a scientific journal of the Cell Press group. Led by Dr. Frédéric Charron, the team of scientists discovered a new requirement for the proper functioning of the Sonic Hedgehog protein.

14 Jun 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

Molecule News and Research

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

Molecularly targeted glue for cancer

VENENUM opens new medicinal chemistry facility in Hamilton, NJ

Two NJIT researchers receive U.S. Patent for nanoprobe array technique

Scientists discover molecular mechanism that could help develop new MS treatments

Novel method of disguising nanoparticles as red blood cells to fight cancer

Palatin receives U.S. patent titled ‘Amino Acid Surrogates for Peptidic Constructs'

TESARO secures $101M in Series B financing

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

Positive data from Ischemix CMX-2043 Phase 2a trial for peri-operative cardiac ischemia-reperfusion injury

Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital

Precisely mapped allosteric binding site will facilitate design of drugs with minimal side effects

Scientists reveal complex protein mechanism that regulates genes linked with cancer

Scientists uncover how immune system responds to invading anthrax bacteria

Positive results from etanercept pilot study against dermatomyositis

UCLA researchers find new potential therapeutic target for preventing HIV

VARI researchers discover protein linked to spread of head and neck cancer nasopharyngeal carcinoma

Scientists discover Sonic Hedgehog protein's mechanism of action

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News